Skip to main content

Table 1 Incidence of adverse reactions within 0–30 days

From: A post-marketing study to evaluate the safety and immunogenicity of a quadrivalent influenza split-virion vaccine in elderly people aged 60 years and older

Item

N

n

Incidences (95%CI)

Overall ARs

1399

53

3.79(2.85 ~ 4.93)

Local ARs

1399

40

2.86(2.05 ~ 3.87)

Systemic ARs

1399

14

1.00(0.55 ~ 1.67)

  1. AR: adverse reaction; CI: confidence intervals;
  2. N: subject number of analyzing set as denominator; n: number of subjects developed corresponding reactions
Back to article page

Tropical Diseases, Travel Medicine and Vaccines

ISSN: 2055-0936

Contact us